TheraRadar
← Back
Data updated: May 24, 2026

CHIESI FARMACEUTICI SPA

Biotech

CHIESI FARMACEUTICI SPA is a biotechnology company focused on Respiratory, Dermatology, Cardiovascular. Key products include MYALEPT.

2014
Since
4
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules 1 Biologics
Novel Drugs (2023):
2 Novel Approvals 1 First-in-Class 1 Orphan Drug

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Respiratory 95%
0 drugs Phase 3: 32 Phase 2: 39 Phase 1: 39
Dermatology 2%
0 drugs Phase 3: 1
Cardiovascular 2%
0 drugs Phase 3: 1
Neurology 2%
0 drugs Phase 2: 2
Gastroenterology 0%
0 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

34
Phase 3
41
Phase 2
40
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • MYALEPT leads revenue
  • 4 key drugs tracked

Trial Catalysts

  • Respiratory pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling